tirzepatide december 19 FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders FDA Says Shortage of GLP-1

The bigger shift: The future of high-demand therapies will be defined by access, pricing, and scalability not just innovation

Most diabetes drugs only target GLP-1 receptors

Bone morphogenetic proteins begin recruiting mesenchymal stem cells from surrounding tissue

doi: 10.3389/fonc.2020.00723 Received 21 February 2020 Accepted 16 April 2020 Published 07 May 2020 Volume 10 - 2020 Edited by Ana Preto, University of Minho, Portugal Reviewed by Cinzia Domenicotti, University of Genoa, Italy

To our knowledge, this is the fifth meta-analysis evaluating the risk of NAION in patients with type 2 diabetes treated with GLP-1 RAs based on observational studies [7578], and the second to focus specifically on semaglutide [75]

This lipid modification allows binding to albumin in the bloodstream